Profil
Michael Woloschak worked as a Senior Director-Medical at Genzyme Corp.
and as a Senior Medical Director at Genzyme Therapeutics Ltd.
He also served as the Vice President-Clinical Development at Soleno Therapeutics, Inc. from 2021 to 2023.
Dr. Woloschak holds a doctorate degree from the University of Toledo Medical Center.
Ehemalige bekannte Positionen von Michael Woloschak
Unternehmen | Position | Ende |
---|---|---|
SOLENO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2023 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Michael Woloschak
University of Toledo Medical Center | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SOLENO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |